Oric Pharmaceuticals undertakes a focused digital transformation to systematize its drug development pipeline for oncology. The company integrates advanced data platforms and specialized systems to manage preclinical research, clinical trials, and regulatory submissions. This approach specifically targets the complex processes required to bring novel small molecule therapies to market, emphasizing precision oncology.
This transformation creates critical dependencies on robust data management and interoperable system architectures. Breakdowns arise from data discrepancies across research platforms and manual interventions in clinical and regulatory workflows. This page analyzes Oric Pharmaceuticals' specific initiatives, the challenges these create, and where external solutions can provide critical support.
Oric Pharmaceuticals Snapshot
Headquarters: South San Francisco, CA, United States
Number of employees: 104 employees
Public or private: Public
Business model: B2B
Website: http://www.oricpharma.com
Oric Pharmaceuticals ICP and Buying Roles
Oric Pharmaceuticals engages with pharmaceutical and biotechnology companies operating in complex clinical development stages.
Who drives buying decisions
- Chief Scientific Officer (CSO) → Oversees R&D data strategies and biomarker development platforms.
- Head of Clinical Operations → Manages clinical trial execution systems and global site coordination.
- Head of Regulatory Affairs → Directs regulatory submission platform management and compliance.
- Director, IT Enterprise Applications → Manages core business systems, including ERP, Finance, Procurement, and supply chain.
Key Digital Transformation Initiatives at Oric Pharmaceuticals (At a Glance)
- Systematizing Clinical Trial Progression: Advancing ORIC-944 and ORIC-114 into registrational studies.
- Integrating Research and Development Data: Centralizing preclinical research, genomics, and chemical library data.
- Standardizing Collaborative Clinical Development Workflows: Harmonizing data and operations with external trial partners.
- Automating Regulatory Affairs Document Management: Streamlining IND and CTA preparation and submission.
- Centralizing Global Clinical Trial Site Management: Coordinating patient enrollment and data collection across international sites.
Where Oric Pharmaceuticals’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Trial Management Systems | Clinical Trial Progression Systematization: patient data entry workflows introduce validation errors. | Head of Clinical Operations, VP of Development | Validate patient data fields against protocol rules during entry. |
| Clinical Trial Progression Systematization: trial documentation does not propagate to regulatory systems. | Head of Regulatory Affairs, Director of Clinical Operations | Standardize document formats and transfer protocols for system handoffs. | |
| Global Clinical Trial Site Management: site monitoring data creates mismatch in central databases. | Head of Clinical Operations, Clinical Data Manager | Enforce data consistency checks from site reports into centralized systems. | |
| R&D Data Integration Platforms | Integrating Research and Development Data: preclinical study results do not sync across research labs. | Chief Scientific Officer, Head of R&D | Standardize data schema and integration points between research instruments. |
| Integrating Research and Development Data: biomarker analysis data creates fragmented reporting. | Head of Translational Science, Director of Data Science | Route biomarker data into a unified analytics platform for consistent reporting. | |
| Regulatory Information Management (RIM) | Automating Regulatory Affairs Document Management: IND application components fail to meet submission standards. | Head of Regulatory Affairs, Regulatory Operations Lead | Enforce document formatting and content rules before regulatory submission. |
| Automating Regulatory Affairs Document Management: CTA submission packages create version control issues. | Regulatory Document Manager, Head of Regulatory Affairs | Prevent concurrent edits and manage document versions across submission teams. | |
| Secure Data Collaboration Platforms | Standardizing Collaborative Clinical Development Workflows: partner data transfers block study progress. | VP of Business Development, Head of Clinical Operations | Standardize data exchange formats and access permissions for external partners. |
| Standardizing Collaborative Clinical Development Workflows: shared trial protocols create compliance gaps. | Head of Quality Assurance, Head of Clinical Development | Enforce shared protocol adherence and document audit trails with collaborators. | |
| Patient Enrollment & Site Optimization | Global Clinical Trial Site Management: patient recruitment metrics do not update in real-time. | Head of Clinical Operations, Director of Patient Recruitment | Detect delays in patient enrollment reporting from global trial sites. |
Identify when companies like Oric Pharmaceuticals are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Oric Pharmaceuticals’s digital transformation unique
Oric Pharmaceuticals prioritizes digital transformation within its core drug development process, specifically for oncology therapies. The company heavily depends on precision data management, integrating complex scientific insights from preclinical research through clinical trials. This makes their transformation distinct by requiring specialized systems for biomarker tracking and resistance mechanism targeting, rather than broad enterprise-wide IT modernization.
Oric Pharmaceuticals’s Digital Transformation: Operational Breakdown
DT Initiative 1: Clinical Trial Progression Systematization
What the company is doing
Oric Pharmaceuticals advances lead product candidates, rinzimetostat (ORIC-944) and enozertinib (ORIC-114), through complex clinical trial phases. The company systematically prepares these candidates for registrational studies in prostate and lung cancer.
Who owns this
- Head of Clinical Operations
- VP of Development
- Clinical Project Managers
Where It Fails
- Clinical data capture forms create inconsistencies between patient visit records.
- Electronic Data Capture (EDC) system data exports contain formatting errors for statistical analysis.
- Trial progress metrics do not update automatically in management dashboards.
- Investigational Product (IP) supply chain data fails to sync with clinical site inventory.
Talk track
Noticed Oric Pharmaceuticals systematizes clinical trial progression for lead candidates. Been looking at how some biopharma teams isolate data inconsistencies at the point of entry instead of correcting errors later, can share what’s working if useful.
DT Initiative 2: Integrating Research and Development Data
What the company is doing
Oric Pharmaceuticals centralizes diverse datasets from preclinical research, including genomics, proteomics, and chemical compound libraries. The company leverages advanced scientific methodologies for biomarker development and novel drug target identification.
Who owns this
- Chief Scientific Officer (CSO)
- Head of R&D
- Director of Data Science
Where It Fails
- Genomic sequencing data fails to integrate with compound screening results in research databases.
- Biomarker assay data creates disparate records across internal analytical systems.
- Preclinical in vivo study results do not transfer consistently into translational research platforms.
- Chemical structure libraries create redundant entries in medicinal chemistry software.
Talk track
Looks like Oric Pharmaceuticals integrates extensive research and development data. Been seeing how some R&D teams standardize data schema and integration points across disparate research instruments instead of manually consolidating data, happy to share what we’re seeing.
DT Initiative 3: Standardizing Collaborative Clinical Development Workflows
What the company is doing
Oric Pharmaceuticals engages in strategic clinical trial collaborations with external partners, like Johnson & Johnson, for combination therapy evaluation. The company develops harmonized operational protocols for shared clinical studies.
Who owns this
- VP of Business Development
- Head of Clinical Operations
- Alliance Management Lead
Where It Fails
- Shared patient consent forms from partners create data entry discrepancies in Oric's systems.
- Clinical data transfers from partner Electronic Data Capture (EDC) systems block data merge processes.
- Joint safety reporting workflows do not enforce consistent adverse event coding.
- Trial monitoring reports from collaborating sites do not align with Oric's quality standards.
Talk track
Saw Oric Pharmaceuticals standardizes collaborative clinical development workflows. Been looking at how some biopharma teams enforce shared data standards and access controls with external partners instead of managing disparate data streams, can share what’s working if useful.
DT Initiative 4: Automating Regulatory Affairs Document Management
What the company is doing
Oric Pharmaceuticals prepares and submits complex Investigational New Drug (IND) and Clinical Trial Application (CTA) documents to global regulatory authorities. The company streamlines workflows for regulatory document assembly and submission.
Who owns this
- Head of Regulatory Affairs
- Regulatory Operations Lead
- Director of Quality Assurance
Where It Fails
- Regulatory submission documents create version conflicts during collaborative authoring.
- Compliance checks for IND sections fail to flag missing data points before submission.
- eCTD publishing software does not assemble components correctly for agency portals.
- Regulatory commitments tracking system records do not update after agency interactions.
Talk track
Seems like Oric Pharmaceuticals automates regulatory affairs document management. Been seeing teams enforce document formatting and content validation rules at the point of creation instead of correcting errors during submission, happy to share what we’re seeing.
Who Should Target Oric Pharmaceuticals Right Now
This account is relevant for:
- Clinical Data Management (CDM) platforms
- Regulatory Information Management (RIM) systems
- R&D Data Orchestration and Integration solutions
- Secure Biopharma Collaboration and Document Sharing platforms
- Clinical Trial Supply Chain Management tools
Not a fit for:
- Generic HR payroll software
- Basic marketing automation tools
- Stand-alone website builders
- Broad-purpose CRM systems without clinical integration
When Oric Pharmaceuticals Is Worth Prioritizing
Prioritize if:
- You sell solutions that prevent patient data entry errors within Electronic Data Capture (EDC) systems.
- You sell platforms that enforce data integrity and schema consistency for preclinical research data.
- You sell secure collaboration tools that standardize data exchange protocols with external clinical partners.
- You sell Regulatory Information Management (RIM) systems that validate submission document compliance.
- You sell clinical supply chain tools that automate inventory tracking and forecast demand for investigational products.
Deprioritize if:
- Your solution does not address specific failures in clinical data management or regulatory compliance.
- Your product is limited to basic data storage without advanced integration capabilities for R&D.
- Your offering is not built for complex, multi-organizational clinical trial environments.
Who Can Sell to Oric Pharmaceuticals Right Now
Clinical Data Management (CDM) Platforms
Medidata Solutions (now part of Dassault Systèmes) - This company provides a unified platform for clinical development, including EDC, coding, and reporting tools.
Why they are relevant: Clinical data capture forms create inconsistencies between patient visit records. Medidata can enforce real-time validation rules during data entry, preventing errors and standardizing data formats before downstream analysis.
Veeva Systems - This company offers cloud-based software for the life sciences industry, including clinical data management solutions.
Why they are relevant: Electronic Data Capture (EDC) system data exports contain formatting errors for statistical analysis. Veeva can standardize data output formats and streamline the export process, ensuring clean data for biostatistical programs.
R&D Data Orchestration and Integration Solutions
Benchling - This company provides a cloud-based informatics platform for biotechnology R&D, centralizing research data and workflows.
Why they are relevant: Genomic sequencing data fails to integrate with compound screening results in research databases. Benchling can unify diverse research data types, establishing a single source of truth for R&D insights.
Dotmatics (now part of Insightful Science) - This company offers scientific software solutions for R&D, including data management and electronic laboratory notebooks (ELN).
Why they are relevant: Preclinical in vivo study results do not transfer consistently into translational research platforms. Dotmatics can standardize data capture and integration from various preclinical experiments into a centralized system.
Regulatory Information Management (RIM) Systems
Extedo - This company provides regulatory information management and electronic Common Technical Document (eCTD) publishing solutions.
Why they are relevant: Regulatory submission documents create version conflicts during collaborative authoring. Extedo can manage document versions and enforce workflow controls across multiple contributors for regulatory filings.
Veeva Vault RIM - This company offers a suite of applications for managing regulatory information, submissions, and quality documents.
Why they are relevant: Compliance checks for IND sections fail to flag missing data points before submission. Veeva Vault RIM can automate content validation and enforce regulatory guidelines within IND applications, preventing submission deficiencies.
Secure Biopharma Collaboration Platforms
Egnyte - This company offers secure content collaboration and data governance solutions for highly regulated industries like life sciences.
Why they are relevant: Shared patient consent forms from partners create data entry discrepancies in Oric's systems. Egnyte can provide a secure, controlled environment for sharing and validating documents with external partners, maintaining data integrity.
Box - This company provides cloud content management and collaboration tools with advanced security and compliance features.
Why they are relevant: Joint safety reporting workflows do not enforce consistent adverse event coding. Box can facilitate controlled document sharing and version management for critical safety reports, ensuring harmonized data collection with collaborators.
Final Take
Oric Pharmaceuticals scales its clinical development and R&D data management for novel oncology therapies. Breakdowns are visible in data consistency across research systems and compliance within global clinical and regulatory workflows. This account is a strong fit for solutions that enforce data integrity, standardize complex scientific data, and streamline regulated document processes within biopharma environments.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.